Market research
EWL.F Edwards Lifesciences Corporation
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 45B
- P/E ratio
- 53.9
- Analyst target
- 119.36
- Dividend yield
- Not available
- Beta
- 0.85
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US28176E1082
- Market cap
- 45B
- P/E ratio
- 53.9
- Analyst target
- 119.36
- Dividend yield
- Not available
- Beta
- 0.85
About
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EWL.F discussion.
5 years, 5 months ago
Edwards Lifesciences Corporation is currently in a long term uptrend where the price is trading 22.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.0.
Edwards Lifesciences Corporation's total revenue rose by 1.5% to $1B since the same quarter in the previous year.
Its net income has increased by 10.5% to $310M since the same quarter in the previous year.
Finally, its free cash flow fell by 12.5% to $287M since the same quarter in the previous year.
Based on the above factors, Edwards Lifesciences Corporation gets an overall score of 4/5.